Immuron North American Travelan® Sales up 494% and Global sales up 431%
July 11 2022 - 6:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company that has developed
two commercially available oral immunotherapeutic products for the
treatment of gut mediated diseases, is pleased to announce the FY22
sales results of its over-the-counter gastrointestinal and
digestive health immune supplement Travelan® and Protectyn®.
North America, Travelan® sales were up by 494%,
reaching AU $0.6M in FY22, compared to AU $0.1M in FY21.
Global sales of Travelan® and Protectyn®
increased by 431% in the 2022 fiscal year to AU $0.9M, compared to
AU $0.2M in FY21.
In the US, Travelan® sales were AU $0.6M for
FY22 compared to only AU $4K in FY21. This growth was attributable
to increasing sales in both Passport Health Travel Clinics and on
the Amazon e- commerce channel. While not at pre-pandemic peak, the
sales numbers in the US are starting to considerably pick up
again.
In Australia, Travelan® and Protectyn® sales
increased to AU $0.3M in FY22 representing a significant increase
over FY21 (AU $0.1M). Coming out of the pandemic restrictions
imposed by Government and with international travel on the increase
we are starting to see positive signs as retail outlets start to
restock product once again.
Immuron is focused on growing its portfolio of
products and has a strong existing pipeline.
*Unaudited gross revenue
COMPANY
CONTACT:Steven
LydeamoreChief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com |
|
|
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases.
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024